Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study

Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study

Abstract Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed...

Full description

Saved in:
Bibliographic Details
Main Authors: Klaus G. Parhofer, Peter Bramlage, Constanze Gries, Cornelia Harder, Christiane Look, W. Dieter Paar, Ursula Rauch-Kröhnert
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-024-00471-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40801-024-00471-w

Similar Items